Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later

This article was originally published in PharmAsia News

Executive Summary

Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators

You may also be interested in...



A Closer Look: Alogliptin's Delay Accelerated Takeda's Pursuit Of Nycomed

Takeda found itself desperate to fill gaps with Actos LOE looming and alogliptin faltering, hastening a 10-year conversation with Nycomed.

A Closer Look: Alogliptin's Delay Accelerated Takeda's Pursuit Of Nycomed

Takeda found itself desperate to fill gaps with Actos LOE looming and alogliptin faltering, hastening a 10-year conversation with Nycomed.

Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China

Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China

Related Content

UsernamePublicRestriction

Register

RS009715

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel